PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF REPLACING PCV13 WITH PCV15 IN THE NATIONAL IMMUNIZATION PROGRAM IN SAUDI ARABIA

被引：0
|
作者：
Huang, M. [1 ]
Weaver, J. [2 ]
Albassam, G. [3 ]
Akel, R. [4 ]
Chhabra, N. [5 ]
Ranjan, S. [5 ]
Gupta, S. [6 ]
Ugrekhelidze, D. [7 ]
机构：
[1] Merck & Co Inc, Merck Res Labs, Rahway, NJ USA
[2] Merck & Co Inc, Rahway, NJ USA
[3] MSD, Riyadh, Saudi Arabia
[4] MSD, Dubai, U Arab Emirates
[5] CHEORS, North Wales, PA USA
[6] CHEORS, Patna, BR, India
[7] MSD, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE562
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Johnna Perdrizet
    Emily K. Horn
    Winniefer Nua
    Judith Perez-Peralta
    Jennifer Nailes
    Jaime Santos
    Anna Ong-Lim
    Infectious Diseases and Therapy, 2021, 10 : 2625 - 2642
  • [22] Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands
    de Vries, L. M.
    Kellerborg, K. M.
    Brouwer, W. B. F.
    van Baal, P. H. M.
    VACCINE, 2021, 39 (29) : 3834 - 3843
  • [23] Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
    Gomez, Jorge A.
    Pinto, Thatiana de Jesus Pereira
    Guevara, Javier Nieto
    Noronha, Tatiana Guimaraes de
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [24] Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection
    Marbaix, Sophie
    Peetermans, Willy E.
    Verhaegen, Jan
    Annemans, Lieven
    Sato, Reiko
    Mignon, Annick
    Atwood, Mark
    Weycker, Derek
    PLOS ONE, 2018, 13 (07):
  • [25] Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13
    Rozenbaum, Mark H.
    Huang, Liping
    Cane, Alejandro
    Arguedas, Adriano
    Chapman, Ruth
    Dillon-Murphy, Desmond
    Tort, Maria J.
    Snow, Vincenza
    Chilson, Erica
    Farkouh, Raymond
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 644 - 652
  • [26] AN INITIAL COST-EFFECTIVENESS ANALYSIS OF THE NEW 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-13) VERSUS PCV-7 IN THE PUBLIC SECTOR OF HONG KONG
    Lee, K. K.
    Chow, D. P.
    Lee, V. W.
    VALUE IN HEALTH, 2010, 13 (03) : A190 - A190
  • [27] Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme
    Farinas, Anai Garcia
    Linares-Perez, Nivaldo
    Clark, Andrew
    Toledo-Romani, Maria Eugenia
    El Omeiri, Nathalie
    Araujo, Martha C. Marrero
    Luis, Isabel Pilar Gonzalvez
    Peraza, Gilda Torano
    Jimenez, Alicia Reyes
    Lopez Ambron, Lena
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 97 : 182 - 189
  • [28] A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION, THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13), OR PCV13 FOLLOWED BY PPV23 IN BRAZIL
    Jiang, Y.
    Yang, X.
    Petigara, T.
    Chabrol Haas, L.
    Graham, J.
    VALUE IN HEALTH, 2017, 20 (09) : A930 - A930
  • [29] COST EFFECTIVENESS OF PCV13 VS PPSV23 FOR THE IMMUNIZATION OF ADULTS OVER 65 YEARS WITH LOW OR MODERATE RISK OF PNEUMOCOCCAL INFECTION
    Baez-Revueltas, F. B.
    Laredo, F.
    VALUE IN HEALTH, 2017, 20 (09) : A931 - A931
  • [30] HEALTH ECONOMIC IMPACT OF INFANT VACCINATION PROGRAM WITH PHID-CV AND PCV13 USING NEW EFFICACY/EFFECTIVENESS DATA. EXAMPLE OF FINLAND
    Delgleize, E.
    Torvinen, S.
    VALUE IN HEALTH, 2012, 15 (07) : A393 - A393
12345